Drug treatment for chronic systolic heart failure.

Abstract

Drug treatment of chronic systolic heart failure usually includes angiotensin-converting enzyme inhibitor, or an angiotensin II receptor blocker, and a beta blocker, as prognostic benefit of these agents has been demonstrated in a large body of clinical trials. Depending on the stage of the disease and concomitant factors, an aldosterone antagonist and/or a digitalis glycoside may provide additional benefit. Most patients also receive a diuretic for symptomatic relief. Conversely, some drugs may precipitate or aggravate chronic systolic heart failure.

• Authors: K Mörike, J R Sindermann
• Journal: The Thoracic and cardiovascular surgeon (Thorac Cardiovasc Surg) Vol. 58 Suppl 2 Pg. S170-2 (Feb 2010) ISSN: 1439-1902 [Electronic] Germany
• PMID: 20101534 (Publication Type: Journal Article, Review)
• Copyright: (c) Georg Thieme Verlag KG Stuttgart-New York.

Chemical References

• Adrenergic beta-Antagonists
• Angiotensin II Type 1 Receptor Blockers
• Angiotensin-Converting Enzyme Inhibitors
• Digitalis Glycosides
• Diuretics
• Mineralocorticoid Receptor Antagonists

Topics

• Adrenergic beta-Antagonists (therapeutic use)
• Angiotensin II Type 1 Receptor Blockers (therapeutic use)
• Angiotensin-Converting Enzyme Inhibitors (therapeutic use)
• Chronic Disease
• Digitalis Glycosides (therapeutic use)
• Diuretics (therapeutic use)
• Heart Failure, Systolic (drug therapy)
• Mineralocorticoid Receptor Antagonists (therapeutic use)
• Treatment Outcome